STOCK TITAN

N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags

N2OFF (NASDAQ: NITO) advanced its European solar portfolio via partner Solterra by providing a $340,000 advance to secure improved development economics and monetization optionality.

As part of an amendment, Solterra accepted a €11,000 per MW reduction in development fees that N2OFF says increases potential project profit by approximately $1.7 million. N2OFF's flagship German project is on track for Q3 2026 approval, with the draft zoning plan due for final consultation in late January 2026 and multiple value-realization pathways expected beginning in H2 2026.

Loading...
Loading translation...

Positive

  • Project on track for Q3 2026 approval
  • Advanced $340,000 to secure better development terms
  • Development-fee cut of €11,000 per MW yields ~$1.7M value

Negative

  • Approval remains pending; final permit expected in Q3 2026
  • Near-term capital redeployed ($340,000) from limited resources

News Market Reaction

%
1 alert
% News Effect
$5M Market Cap
0.1x Rel. Volume

On the day this news was published, NITO declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Advance payment: $340,000 Project profit uplift: Approximately $1.7 million Fee reduction: €11,000 per MW +3 more
6 metrics
Advance payment $340,000 Advanced to Solterra for German flagship solar project
Project profit uplift Approximately $1.7 million Incremental project-level value from revised profit stake
Fee reduction €11,000 per MW Reduction in development fees under amended agreement
Approval timing Q3 2026 Expected permitting approval for German solar project
Monetization window H2 2026 Start of value realization pathways for portfolio
Zoning submission Late January 2026 Planned draft zoning plan submission for final consultation

Market Reality Check

Price: $1.26 Vol: Volume 18,792 is below th...
low vol
$1.26 Last Close
Volume Volume 18,792 is below the 20-day average of 30,146 (relative volume 0.62). low
Technical Shares closed at $1.59, trading below the 200-day MA at $6.92 and far under the $122.15 52-week high.

Peers on Argus

Sector peers were mixed, with moves from -31.47% (SANW) to +40.35% (ENFY). Momen...
1 Down

Sector peers were mixed, with moves from -31.47% (SANW) to +40.35% (ENFY). Momentum scanner only flagged LVRO at -15.46%, reinforcing that N2OFF’s move appears stock-specific rather than a broad agricultural inputs trade.

Historical Context

5 past events · Latest: Dec 29 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
Dec 29 Renewables portfolio update Positive -19.4% De-risking German and Italian solar assets and ~$1.69M project value savings.
Nov 18 Drug discovery update Positive +0.7% MitoCareX hit compounds identified and 2026 preclinical candidate plans outlined.
Oct 30 Acquisition completion Positive -0.9% Completed MitoCareX merger with cash and large equity component to sellers.
Oct 23 Merger closing PR Positive +6.8% Announced closing of MitoCareX merger targeting resistant cancers.
Oct 08 Nasdaq compliance Positive -10.7% Regained Nasdaq minimum bid compliance after prior deficiency and RTB strategy update.
Pattern Detected

Several positive strategic updates, including de-risking solar assets and regaining listing compliance, previously saw negative price reactions, suggesting a pattern of selling into good news.

Recent Company History

Over the last few months, N2OFF has shifted toward a dual story of drug discovery and renewable energy. On Oct 8, 2025 it regained Nasdaq bid-price compliance but the stock fell, and subsequent filings detailed a 1-for-35 reverse split and going concern warning. In October 2025 it closed the MitoCareX acquisition through cash and significant equity issuance, followed by a shareholder letter on the MITOLINE™ platform. On Dec 29, 2025, N2OFF highlighted de-risking of European solar projects and about $1.69M in value savings, which again met a negative price reaction. Today’s update extends that same German RTB solar narrative.

Market Pulse Summary

This announcement refines N2OFF’s German RTB solar project economics, exchanging a $340,000 advance ...
Analysis

This announcement refines N2OFF’s German RTB solar project economics, exchanging a $340,000 advance payment for development-fee cuts that add about $1.7 million in project value and target approval in Q3 2026. It builds directly on the Dec 29, 2025 de-risking update and reinforces a focus on capital-efficient asset value. Against prior disclosures of a going concern warning and significant equity issuances, future updates on execution, funding, and monetization in H2 2026 remain important watchpoints.

AI-generated analysis. Not financial advice.

Neve Yarak, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. (“Solterra”). As announced on December 29, 2025, key milestones in Germany project, which includes solar energy PV and storage assets, have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality.

Key Investor Highlights

  • Reduction in permitting and regulatory risk across core European assets
  • Advanced payment of $340,000 and receiving favourable terms in the project’s profit stake
  • Approximately $1.7 million in project-level value creation achieved through disciplined renegotiation of development economics
  • Enhanced monetization optionality, with multiple high-visibility pathways to value realization beginning in H2 2026

Germany Update: on track for Q3 2026 approval with savings secured

N2OFF’s flagship German solar project has advanced into the final stages of the permitting process and remains firmly on track toward expected approval in Q3 2026.

The first public consultation phase is nearing completion with no objections or material modification requests to date, a strong indicator of regulatory alignment, community acceptance, and planning integrity. Submission of the draft zoning plan for the final consultation phase is scheduled for late January 2026 following the holiday period, maintaining a clear development timeline.

In a demonstration of proactive value optimization, Solterra has indicated that an amendment to the development agreement was executed last week. Solterra will receive approximately $340,000 in advance funding to fuel faster progress, in exchange for a €11,000 per MW reduction in development fees, thereby increasing potential profit with approximately $ 1.7 million.

From a capital allocation perspective, this transaction represents a highly efficient redeployment of limited near-term capital to materially improve long-term project economics, increase embedded equity value, and enhance future exit or operating returns.

Strategic Perspective

The recent developments in Germany advance the Company’s European portfolio along the RTB value curve. By systematically reducing regulatory risk, tightening development economics, and preserving monetization flexibility, N2OFF continues to position itself as a disciplined capital allocator focused on scalable, infrastructure-backed value creation.

About N2OFF Inc:

N2OFF owns 100% of MitoCareX Bio Ltd, a drug delivery company engaged in drug discovery targeting cancer therapeutics and other diseases through the mitochondrial SLC25 protein family. Additionally, N2OFF adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build ) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd

N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.

For more information, please visit www.n2off.com.

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties including the success of our collaboration with Solterra Energy Ltd., entry into future projects, our ability to successfully enter the solar PV sector, the profitability of such industry, and the potential added value of the increased capacity. Actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including market conditions as well as those discussed under the heading “Risk Factors” in N2OFF’s Annual Report on Form 10-K filed with the SEC on March 31, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com


FAQ

What did N2OFF (NITO) announce about its German solar project on January 5, 2026?

N2OFF announced a $340,000 advance to Solterra, a €11,000 per MW fee reduction, and ~$1.7M project-level value creation while targeting Q3 2026 approval.

How does the $340,000 advance affect N2OFF's project economics (NITO)?

The advance secured a €11,000 per MW reduction in development fees, which N2OFF says increases potential project profit by ~$1.7M.

When is N2OFF expecting final permitting approval for the German project (NITO)?

The company reports the German project is on track for final approval in Q3 2026, with a draft zoning plan scheduled for late January 2026.

What monetization timeline did N2OFF give for its European solar assets (NITO)?

N2OFF indicated multiple high-visibility monetization pathways could begin in H2 2026.

What specific fee change did Solterra agree to in the amendment with N2OFF (NITO)?

Solterra agreed to a €11,000 per MW reduction in development fees in exchange for the $340,000 advance.

Does the announcement state the German permit is already granted for N2OFF (NITO)?

No; the announcement says the project is in final permitting stages and remains on track for expected approval in Q3 2026.
N2OFF INC

NASDAQ:NITO

NITO Rankings

NITO Latest News

NITO Latest SEC Filings

NITO Stock Data

3.42M
1.41M
16.84%
1.34%
2.04%
Agricultural Inputs
Agricultural Chemicals
Link
Israel
NEW YORK